Your browser doesn't support javascript.
loading
A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies.
Liu, Zhiwei; Liu, Yingluo; Qian, Lili; Jiang, Shangwen; Gai, Xiameng; Ye, Shu; Chen, Yuehong; Wang, Xiaomin; Zhai, Linhui; Xu, Jun; Pu, Congying; Li, Jing; He, Fuchu; Huang, Min; Tan, Minjia.
Afiliação
  • Liu Z; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China.
  • Liu Y; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China.
  • Qian L; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Jiang S; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Gai X; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China.
  • Ye S; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Chen Y; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Wang X; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Zhai L; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China; Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy
  • Xu J; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Pu C; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China.
  • Li J; Department of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
  • He F; State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China.
  • Huang M; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China. Electronic address: mhuang@s
  • Tan M; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China. Electronic address: mjtan@si
Mol Cell ; 81(19): 4076-4090.e8, 2021 10 07.
Article em En | MEDLINE | ID: mdl-34375582
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fosfoproteínas / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogênicas p21(ras) / Proteoma / Proteômica / Inibidores Enzimáticos / Mutação / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Mol Cell Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fosfoproteínas / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogênicas p21(ras) / Proteoma / Proteômica / Inibidores Enzimáticos / Mutação / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Mol Cell Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China